Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

Related Keywords

Zurich ,Züsz ,Switzerland ,Frankfurt ,Brandenburg ,Germany ,Swiss ,Stig Hansen ,Thomas Schinecker ,Sharon Singleton ,Roche Graham ,Eli Lilly ,Teresa Graham ,Zuercher Kantonalbank ,Ludwig Burger ,Lilly Mounjaro ,Noel Illien ,Astrazeneca ,Pfizer ,Novo Nordisk ,Reuters ,Carmot Therapeutics ,Kimia Therapeutics ,Frankfurt Additional ,Rachel More ,Louise Heavens ,Weight Management ,Obesity ,Bese ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Weight Loss ,Drug Development ,Drug Discovery ,Drug Pipeline ,Drug Development Pipeline ,